MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/600/0.01/20.12.24 | Market Closed - Börse Stuttgart 03:23:46 2024-06-07 pm EDT | ||
| 0.129 EUR | 0.00% |
|
| Current month | +53.41% | ||
| 1 month | +92.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 0.135 | +4.65% |
| 24-06-06 | 0.129 | +0.78% |
| 24-06-05 | 0.128 | +6.67% |
| 24-06-04 | 0.12 | +12.15% |
| 24-06-03 | 0.107 | +21.59% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 03:23 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME66EG |
| ISIN | DE000ME66EG2 |
| Date issued | 2024-01-02 |
| Strike | 600 $ |
| Maturity | 2024-12-20 (195 Days) |
| Parity | 100 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.158 € |
|---|---|
| Lowest since issue | 0.057 € |
| Spread | 0.01 € |
| Spread % | 7.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
